Tumores del estroma gastrointestinal: Análisis de 40 casos / Gastrointestinal stromal tumors. Analysis of 40 cases

Los tumores del estroma gastrointestinal representan menos del 3% de los tumores digestivos. Se localizan principalmente en el estómago y el intestino delgado. El tratamiento radical es la resección quirúrgica. Cuando son inoperables o diseminados la administración de imatinib es el tratamiento de elección. La finalidad de este estudio retrospectivo fue describir las características de los pacientes con tumores del estroma gastrointestinal atendidos en nuestra institución en el período 2000-2015. Fueron analizados los casos de 40 pacientes consecutivos con diagnóstico de tumor del estroma gastrointestinal (edad media 58 años, rango 33-84). La supervivencia media a 5 años del total de pacientes fue 30.5%. Al diagnóstico, 30 (75%) tenían enfermedad localizada; de estos, 14 recibieron imatinib adyuvante y 15 seguimiento en observación. En este grupo, el intervalo libre de enfermedad fue 55 meses. En aquellos con enfermedad diseminada, el intervalo libre de progresión fue 30 meses.

Gastrointestinal stromal tumors represent less than 3% of all digestive tumors. They are primarily located in the stomach and the small intestine. The curative treatment is surgical resection. In the case of unresectable tumor or advanced disease, imatinib is the treatment of choice. The purpose of this retrospective study was to describe the characteristics of patients with gastrointestinal stromal tumors treated at our institution in the period 2000-2015. We analyzed 40 consecutive patients diagnosed with gastrointestinal stromal tumor (mean age 58-year old, range 33-84). The mean 5-year survival was 30.5%. At diagnosis, 30 patients had localized disease (75%); 14 of them received adjuvant imatinib and 15 follow-up on observation. In this group the disease-free interval was 55 months. In patients with advanced disease, the progression-free interval was 30 months.

Knowledge, attitudes, and practices toward onchocerciasis among local population in Bioko Island, Equatorial Guinea

Introduction: Since 1998, the African program for onchocerciasis control has been working with ultimate goal of reducing the public health impact associated with onchocerciasis in Equatorial Guinea. Although dedicated community engagement is crucial for the success of this program, there is no information on the levels of community's knowledge, attitude, and practice (KAP) toward onchocerciasis in this country. Methods: A cross-sectional study was carried out in Bioko Island from mid-January to mid-February 2014. Sampling was carried out by multistage cluster survey. Sociodemographic characteristics, KAP, and stigma-related questions were collected through a pretested questionnaire. A bivariate analysis was performed and results were adjusted by sex and age using logistic regression. Results: A total of 140 housekeepers or head of households agreed to participate. Around 54% of the interviewees had heard about the disease, of which more than one-third identified the disease as filariasis (28/68, 41.2%). Overall, 19.3% respondents highlighted the bite of a blackfly as the main mode of transmission. From those who had a familiar affected by onchocerciasis in the past, 21 out of 32 (65.6%) pointed ivermectin as the preferred treatment and 43.8% pointed out the health center as the first choice place to seek for treatment. About 67.1% of individuals believed that having onchocerciasis would not cause any contact avoidance with other members in the community. Conclusions: People's practices toward onchocerciasis tend to be better than disease knowledge in Bioko Island. Increasing awareness through community-based campaigns and educational activities is encouraged in the current onchocerciasis preelimination stage at Bioko Island